AR102177A1 - Compuestos de heteroarilo como inhibidores de btk y usos de los mismos - Google Patents

Compuestos de heteroarilo como inhibidores de btk y usos de los mismos

Info

Publication number
AR102177A1
AR102177A1 ARP150103209A ARP150103209A AR102177A1 AR 102177 A1 AR102177 A1 AR 102177A1 AR P150103209 A ARP150103209 A AR P150103209A AR P150103209 A ARP150103209 A AR P150103209A AR 102177 A1 AR102177 A1 AR 102177A1
Authority
AR
Argentina
Prior art keywords
ring
sulfur
nitrogen
oxygen
independently selected
Prior art date
Application number
ARP150103209A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54337891&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR102177(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR102177A1 publication Critical patent/AR102177A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Compuestos de imidazo piridina, y composiciones farmacéuticamente aceptables de los mismos, útiles como inhibidores de BTK. Reivindicación 1: Un compuesto de fórmula (1), o un tautómero, o una sal farmacéuticamente aceptable del mismo, donde: el Anillo A es un arilo o heteroarilo de 5 a 6 miembros; R¹ es H, halo, (C(R⁵)(R⁵))ₘNR², N(R⁴)C(O)R, N(R⁴)C(O)NR₂, N(R⁴)CO₂R, N(R⁴)S(O)₂R, N(R⁴)S(O)R, N(R⁴)(R⁴), anillo heterocíclico opcionalmente sustituido de 3 a 7 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre, o anillo heteroarilo monocíclico opcionalmente sustituido de 5 a 6 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre; o R¹ está ausente; R² es H, (C(R⁵)(R⁵))ₘOR⁴, (C(R⁵)(R⁵))ₘN(R⁴)COR, (C(R⁵)(R⁵))ₘN(R⁴)C(O)C(O)NR₂, (C(R⁵)(R⁵))ₘN(R⁴)(R⁴), anillo heterocíclico opcionalmente sustituido de 3 a 7 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre, o anillo heteroarilo monocíclico opcionalmente sustituido de 5 a 6 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre; o R² está ausente; o R¹ y R² junto con los átomos a los que están conectados, forman un anillo condensado de 3 a 7 miembros que está opcionalmente sustituido; donde R¹ y R² no son ninguno H; y donde R¹ y R² no está ninguno ausente; cada R³ es independientemente halógeno, alifático C₁₋₆, arilo C₅₋₁₀, un anillo carbocíclico saturado o parcialmente insaturado de 3 a 8 miembros, un anillo heterocíclico de 3 a 7 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre, o un anillo heteroarilo monocíclico de 5 a 6 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre; cada uno de los cuales está opcionalmente sustituido; cada R⁴ es independientemente -R, -SO₂R, -SOR, -C(O)R, -CO₂R o -C(O)N(R)₂; cada R⁵ es independientemente -R, halógeno, -OR, -SR, -CN, -NO₂, -SO₂R, -SOR, -C(O)R, -CO₂R, -C(O)N(R)₂, -NRC(O)R, -NRC(O)N(R)₂, -NRSO₂R o -N(R)₂; cada R es independientemente hidrógeno, alifático C₁₋₆, arilo C₅₋₁₀, un anillo carbocíclico saturado o parcialmente insaturado de 3 a 8 miembros, un anillo heterocíclico de 3 a 7 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre, o un anillo heteroarilo monocíclico de 5 a 6 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre; cada uno de los cuales está opcionalmente sustituido; o dos grupos R en el mismo átomo se toman junto con el átomo al que están unidos para formar un arilo C₅₋₁₀, un anillo carbocíclico saturado o parcialmente insaturado de 3 a 8 miembros, un anillo heterocíclico de 3 a 7 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre, un anillo heteroarilo monocíclico de 5 a 6 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre; un anillo arilo condensado de 10 a 15 miembros; un anillo carbocíclico condensado saturado o parcialmente insaturado de 6 a 15 miembros; un anillo heteroarilo condensado de 10 a 15 miembros; o un anillo heterocíclico condensado saturado o parcialmente insaturado de 6 a 15 miembros; cada uno de los cuales está opcionalmente sustituido; el Anillo Z es arilo C₅₋₁₀, un anillo carbocíclico saturado o parcialmente insaturado de 3 a 8 miembros, un anillo heterocíclico de 3 a 7 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre, o un anillo heteroarilo monocíclico de 5 a 6 miembros que tiene 1 - 4 heteroátomos independientemente seleccionados entre nitrógeno, oxígeno o azufre; cada uno de los cuales está opcionalmente sustituido; o el Anillo Z está ausente; cada Rᵃ es independientemente -R, halógeno, -OR, -SR, -CN, -NO₂, -SO₂R, -SOR, -C(O)R, -CO₂R, -C(O)N(R)₂, -NRC(O)R, -NRC(O)N(R)₂, -NRSO₂R o -N(R)₂; m es 1, 2 ó 3; n es 0, 1 ó 2; y p es 0, 1, 2 ó 3.
ARP150103209A 2014-10-06 2015-10-06 Compuestos de heteroarilo como inhibidores de btk y usos de los mismos AR102177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462060249P 2014-10-06 2014-10-06

Publications (1)

Publication Number Publication Date
AR102177A1 true AR102177A1 (es) 2017-02-08

Family

ID=54337891

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103209A AR102177A1 (es) 2014-10-06 2015-10-06 Compuestos de heteroarilo como inhibidores de btk y usos de los mismos

Country Status (19)

Country Link
US (2) US10253023B2 (es)
EP (1) EP3204382B1 (es)
JP (1) JP6856526B2 (es)
KR (1) KR102523111B1 (es)
CN (1) CN107001362A (es)
AR (1) AR102177A1 (es)
AU (1) AU2015328285B2 (es)
BR (1) BR112017006305B1 (es)
CA (1) CA2960401C (es)
CL (1) CL2017000786A1 (es)
ES (1) ES2907622T3 (es)
IL (1) IL251441B (es)
MX (1) MX2017004200A (es)
NZ (1) NZ729603A (es)
PH (1) PH12017500408B1 (es)
RU (1) RU2742122C2 (es)
SG (1) SG11201701573QA (es)
WO (1) WO2016057500A1 (es)
ZA (1) ZA201701501B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57662B1 (sr) * 2013-12-11 2018-11-30 Biogen Ma Inc Biaril jedinjenja korisna za lečenje humanih bolesti u onkologiji, neurologiji i imunologiji
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017112730A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
PL3472167T3 (pl) 2016-06-20 2022-12-19 Incyte Corporation Związki heterocykliczne jako immunomodulatory
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CA3034239A1 (en) * 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN109923114B (zh) 2016-09-09 2022-11-01 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112019012993A2 (pt) 2016-12-22 2019-12-03 Incyte Corp derivados de benzo-oxazol como imunomoduladores
CR20190317A (es) 2016-12-22 2019-09-13 Incyte Corp Compuestos inmunomodulares y métodos de uso
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CN106939009A (zh) * 2017-03-31 2017-07-11 牡丹江医学院 一种用于治疗脑震荡的药物及其制备方法
JOP20190233A1 (ar) * 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
WO2019099294A1 (en) * 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
MX2020008656A (es) 2018-02-20 2020-12-09 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer.
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
AU2019245288C1 (en) 2018-03-30 2024-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
CA3099994A1 (en) 2018-05-11 2019-11-04 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CN110256446B (zh) * 2018-08-01 2021-12-14 上海海雁医药科技有限公司 苯并杂环取代的环戊二烯并[4,5]吡咯并吡嗪-1-酮衍生物及其应用
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP2021535133A (ja) * 2018-08-28 2021-12-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ブルトン型チロシンキナーゼ（ｂｔｋ）の可逆的阻害剤としての縮合イミダゾピリジン
JP7399968B2 (ja) 2018-09-25 2023-12-18 インサイト・コーポレイション Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제
AR119624A1 (es) 2019-08-09 2021-12-29 Incyte Corp Sales de un inhibidor de pd-1 / pd-l1
US20220396575A1 (en) * 2019-08-30 2022-12-15 Tsd Life Sciences Co., Ltd. Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
WO2021060307A1 (ja) * 2019-09-25 2021-04-01 富士フイルム株式会社 イミダゾピリジン化合物またはその塩および医薬組成物
JP2022549375A (ja) 2019-09-30 2022-11-24 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
EP4055011A1 (en) * 2019-11-05 2022-09-14 Dermira, Inc Mrgprx2 antagonists and uses thereof
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
MX2022005651A (es) 2019-11-11 2022-07-27 Incyte Corp Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115151535A (zh) 2020-02-20 2022-10-04 和记黄埔医药（上海）有限公司 杂芳基杂环化合物及其用途
CN111171065A (zh) * 2020-02-26 2020-05-19 上海博黑生物科技有限公司 一种(4-(1-((叔丁氧基羰基)氨基)环丙基)苯基)硼酸酯的合成方法
CN111423435B (zh) * 2020-03-30 2021-10-15 厦门大学 (1H-咪唑并[4,5-b]吡啶-6-基)吡啶衍生物及其应用
WO2021219071A1 (en) * 2020-04-30 2021-11-04 Beigene (Beijing) Co., Ltd. Process for preparing protac btk degraders
AU2021343591A1 (en) * 2020-09-21 2023-05-04 Hutchison Medipharma Limited Heteroaryl heterocyclic compounds and uses thereof
CN116234550A (zh) * 2020-09-23 2023-06-06 劲方医药科技(上海)有限公司 芳甲酰取代的三环化合物及其制法和用途
CN114478528A (zh) * 2020-10-28 2022-05-13 劲方医药科技(上海)有限公司 芳甲酰取代的三环化合物及其制法和用途
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2023174300A1 (zh) * 2022-03-15 2023-09-21 劲方医药科技(上海)有限公司 Btk抑制剂的晶型及其酸式盐和其酸式盐的晶型

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314936B2 (en) * 2002-01-07 2008-01-01 Eisai Co., Ltd. Deazapurines and uses thereof
UY29825A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
WO2008011557A2 (en) * 2006-07-20 2008-01-24 Borchardt Allen J Heteroaryl inhibitors of rho kinase
AU2009266806A1 (en) * 2008-07-03 2010-01-07 Exelixis Inc. CDK modulators
WO2010036316A1 (en) * 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
WO2011043491A1 (ja) 2009-10-06 2011-04-14 独立行政法人理化学研究所 新規蛍光性人工塩基
AR086992A1 (es) * 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
EP2729466B1 (en) * 2011-07-08 2015-08-19 Novartis AG Novel pyrrolo pyrimidine derivatives
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
EP2838898B1 (en) * 2012-04-20 2017-01-18 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
CA2881070A1 (en) * 2012-10-26 2014-05-01 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
EP3080122B1 (en) * 2013-12-11 2018-10-31 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Also Published As

Publication number Publication date
RU2742122C2 (ru) 2021-02-02
PH12017500408A1 (en) 2017-07-17
BR112017006305A2 (pt) 2017-12-12
RU2017115852A (ru) 2018-11-12
SG11201701573QA (en) 2017-03-30
KR102523111B1 (ko) 2023-04-18
US20190233417A1 (en) 2019-08-01
PH12017500408B1 (en) 2017-07-17
WO2016057500A1 (en) 2016-04-14
EP3204382A1 (en) 2017-08-16
JP2017533897A (ja) 2017-11-16
KR20170066566A (ko) 2017-06-14
CN107001362A (zh) 2017-08-01
US20160096834A1 (en) 2016-04-07
IL251441B (en) 2020-06-30
BR112017006305B1 (pt) 2024-02-20
US10253023B2 (en) 2019-04-09
AU2015328285B2 (en) 2019-07-18
CA2960401C (en) 2022-07-26
MX2017004200A (es) 2017-06-15
ZA201701501B (en) 2019-06-26
RU2017115852A3 (es) 2019-04-19
IL251441A0 (en) 2017-05-29
NZ729603A (en) 2022-02-25
US11098041B2 (en) 2021-08-24
CL2017000786A1 (es) 2017-12-29
CA2960401A1 (en) 2016-04-14
EP3204382B1 (en) 2021-12-01
AU2015328285A1 (en) 2017-03-23
JP6856526B2 (ja) 2021-04-07
ES2907622T3 (es) 2022-04-25

Similar Documents

Publication Publication Date Title
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR106798A1 (es) Inhibidores pirazol de acc y usos de los mismos
AR106763A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR100058A1 (es) DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR096241A1 (es) Inhibidores de acc y usos de los mismos
AR101395A1 (es) Derivados de indolizina y su uso en enfermedades neurodegenerativas
AR099785A1 (es) Compuestos heteroarilos y su uso como medicamentos
AR111407A1 (es) Compuestos inhibidores de ask1 y usos de los mismos
AR094300A1 (es) Derivados de quinolonas
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR100724A1 (es) Derivados de quinolina y su uso en enfermedades neurodegenerativas
AR095040A1 (es) Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina
AR100440A1 (es) Derivados de carboxamida como inhibidores selectivos de smurf1
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR090376A1 (es) Compuestos herbicidas
AR114496A1 (es) Compuestos antiproliferación y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure